Ilan Oren serves as Co-Chief Executive Officer at Dexcel Pharma, a privately-held international pharmaceutical company involved in the development, manufacture, and commercialization of pharmaceuticals.
At Dexcel Pharma, Mr. Oren is also responsible for new venture formation and strategic investments in biotech companies. Mr. Oren currently serves as a board director of Roivant Sciences, Axovant Sciences, and Kriya Therapeutics.
He was previously a board member of Cynapsus Therapeutics, a publicly-listed CNS company, until its acquisition by Sunovion in 2016. Mr. Oren received his B.A. in Economics from Harvard College.